NSEI:BALPHARMA

Stock Analysis Report

Executive Summary

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

Snowflake

Fundamentals

Second-rate dividend payer with imperfect balance sheet.

Share Price & News

How has Bal Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.3%

BALPHARMA

4.0%

IN Pharmaceuticals

2.4%

IN Market


1 Year Return

-52.1%

BALPHARMA

-13.9%

IN Pharmaceuticals

8.0%

IN Market

Return vs Industry: BALPHARMA underperformed the Indian Pharmaceuticals industry which returned -13.9% over the past year.

Return vs Market: BALPHARMA underperformed the Indian Market which returned 8% over the past year.


Shareholder returns

BALPHARMAIndustryMarket
7 Day-0.3%4.0%2.4%
30 Day-8.1%-2.8%2.5%
90 Day-19.8%0.7%3.6%
1 Year-51.1%-52.1%-13.1%-13.9%10.3%8.0%
3 Year-66.6%-67.9%-24.6%-26.2%22.3%16.0%
5 Year-43.1%-46.9%-10.2%-12.9%42.8%29.3%

Price Volatility Vs. Market

How volatile is Bal Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bal Pharma undervalued compared to its fair value and its price relative to the market?

0.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: BALPHARMA (₹37.55) is trading above our estimate of fair value (₹6.94)

Significantly Below Fair Value: BALPHARMA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BALPHARMA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: BALPHARMA is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BALPHARMA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BALPHARMA is good value based on its PB Ratio (0.8x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Bal Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bal Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bal Pharma performed over the past 5 years?

-30.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BALPHARMA is unprofitable, and losses have increased over the past 5 years at a rate of -30.2% per year.

Accelerating Growth: Unable to compare BALPHARMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BALPHARMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.2%).


Return on Equity

High ROE: BALPHARMA has a negative Return on Equity (-3.49%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BALPHARMA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BALPHARMA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Bal Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: BALPHARMA's short term assets (₹1.8B) exceeds its short term liabilities (₹1.6B)

Long Term Liabilities: BALPHARMA's short term assets (1.8B) exceeds its long term liabilities (378.6M)


Debt to Equity History and Analysis

Debt Level: BALPHARMA's debt to equity ratio (214.6%) is considered high

Reducing Debt: BALPHARMA's debt to equity ratio has increased from 101.1% to 214.6% over the past 5 years.

Debt Coverage: BALPHARMA's debt is not well covered by operating cash flow (6%).

Interest Coverage: BALPHARMA is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet

Inventory Level: BALPHARMA has a high level of physical assets or inventory.

Debt Coverage by Assets: BALPHARMA's debt is covered by short term assets (assets are 1.407590x debt).


Next Steps

Dividend

What is Bal Pharma's current dividend yield, its reliability and sustainability?

2.61%

Current Dividend Yield


Dividend Yield vs Market

company2.6%marketbottom25%0.6%markettop25%2.4%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: BALPHARMA's dividend (2.61%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: BALPHARMA's dividend (2.61%) is in the top 25% of dividend payers in the Indian market (2.41%)

Stable Dividend: BALPHARMA's dividend payments have been volatile in the past 10 years.

Growing Dividend: BALPHARMA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: BALPHARMA is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Bal Pharma's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Shailesh Siroya (53yo)

0.8yrs

Tenure

₹8,000,000

Compensation

Mr. Shailesh Dheerajmal Siroya serves as the Managing Director of BAL Pharma Limited. Mr. Siroya served as the Managing Director of BAL Pharma Limited since August 1, 1994. With rich experience, Mr. Siroya ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Shailesh's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Shailesh's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

0.8yrs

Average Tenure

53yo

Average Age

Experienced Management: BALPHARMA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

6.0yrs

Average Tenure

53yo

Average Age

Experienced Board: BALPHARMA's board of directors are considered experienced (6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Shailesh Siroya (53yo)

    MD & Executive Director

    • Tenure: 0.8yrs
    • Compensation: ₹8.00m
  • Subba Prasanna (71yo)

    Whole Time Director

    • Tenure: 25.2yrs
    • Compensation: ₹3.18m
  • Archana Mitra (45yo)

    Vice President of International Marketing and Marketing Professional

    • Tenure: 0yrs
  • M. George

    Production Advisor

    • Tenure: 0yrs
  • Ravindra Kothari (64yo)

    Deputy General Manager of Internal Audit

    • Tenure: 0yrs
  • Nabjit Sharma (40yo)

    General Manager of International Marketing

    • Tenure: 0yrs
  • A.N.V.K Chaitanya

    Chief Financial Officer

    • Tenure: 1.1yrs
  • Prerna Jain

    Company Secretary & Compliance Officer

    • Tenure: 0.08yrs

Board Members

  • Shailesh Siroya (53yo)

    MD & Executive Director

    • Tenure: 0.8yrs
    • Compensation: ₹8.00m
  • Subba Prasanna (71yo)

    Whole Time Director

    • Tenure: 25.2yrs
    • Compensation: ₹3.18m
  • S. Kumar (51yo)

    Independent Non-Executive Director

    • Tenure: 7.4yrs
    • Compensation: ₹8.00k
  • Premchand Bhantia Bhandari (51yo)

    Additional Independent Director

    • Tenure: 4.6yrs
    • Compensation: ₹8.00k
  • C.V. Srinivas (53yo)

    Additional Independent Director

    • Tenure: 0.3yrs
  • Himesh Virupakshaya

    Executive & Non Independent Additional Director

    • Tenure: 0.08yrs

Company Information

Bal Pharma Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bal Pharma Limited
  • Ticker: BALPHARMA
  • Exchange: NSEI
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹542.802m
  • Shares outstanding: 14.17m
  • Website: https://www.balpharma.com

Location

  • Bal Pharma Limited
  • Lakshmi Narayan Complex
  • 5th Floor
  • Bengaluru
  • Karnataka
  • 560052
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524824BSE (Mumbai Stock Exchange)YesEquity SharesININRJan 2002
BALPHARMANSEI (National Stock Exchange of India)YesEquity SharesININRJan 2002

Biography

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC produ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 12:45
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.